Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

-related signs and symptoms (7.3% with ARCALYST and 7.3% with placebo), and taking more than the recommended dose (5.6% with ARCALYST and 6.4% with placebo).

About GoutGout is a condition that occurs when the bodily waste product, uric acid, is deposited in the joints and/or soft tissues.  In the joints, these uric acid crystals cause inflammation, which leads to pain, swelling, redness, heat, and stiffness in the joints.  Treatment guidelines recommend that patients with elevated uric acid levels who experience multiple gout attacks each year should receive chronic uric acid-lowering therapy, such as allopurinol.  Allopurinol reduces the production of uric acid in the body to prevent the occurrence of gout attacks with long-term use.  Approximately 750,000 gout patients initiate allopurinol therapy each year.  During the first months of allopurinol therapy while uric acid blood levels are being reduced, the break up of the uric acid crystals can result in stimulation of inflammatory mediators, including interleukin-1 (IL-1), resulting in acute flares of joint pain and inflammation.  Anti-inflammatory therapy with colchicine is sometimes used to help prevent these flares.  However, the side effects associated with colchicine, which include diarrhea, abdominal cramps, nausea, and vomiting, can limit patients' adherence to both colchicine and allopurinol treatment.

Rationale for the Clinical Exploration of Use of ARCALYST® (rilonacept) in the Treatment of GoutInterleukin-1 (IL-1) is a protein secreted by infection-fighting cells in the blood and tissues.  In many cases, IL-1 acts as a messenger to help regulate immune and inflammatory responses by attaching to cell-surface receptors in cells that participate in the body's immune system.  In excess, it can be harmful and has been shown to be a key driver of inflammation in a variety of diseases, including gout.  In gout, uric acid crystals stimu
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or ... products, announced today that the Company will present at the ... 2013 at the Le Parker Meridian hotel, 119 W. 56 ... . The presentation is scheduled to begin at 2:15 p.m. ... Heska Heska Corporation (NASDAQ: HSKA - ...
(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- World markets ... with the latest trends and events, companies now ... predict where an industry is headed next, so ... (Photo: http://photos.prnewswire.com/prnh/20130522/CG19099 ) ... market research publisher GlobalData, offer decision makers and ...
(Date:5/22/2013)... Calif. , May 22, 2013   Accuray ... that its management is scheduled to present at the ... York on Thursday, June 6, 2013 at ... webcast of the presentation will be available online from ... http://www.accuray.com/investors . The webcast replay of the ...
Breaking Medicine Technology:Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 3Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 4
... TOKYO, May 22, 2007 /PRNewswire-FirstCall/ -- Sosei ... the,successful completion of a study of its ... for the treatment of cancer,breakthrough pain. , ... centre, open-label,single dose, cross-over, randomised study of ...
... /PRNewswire/ -- A three-year,follow-up subset analysis presented today ... that the CYPHER(R),Sirolimus-eluting Coronary Stent had results comparable ... and better outcomes,than bare metal stents (BMS) in ... arteries. , The CYPHER(R) Stent results in the ...
Cached Medicine Technology:Sosei Announces Successful Completion of AD 923 Pharmacokinetic,Study in the USA 2Sosei Announces Successful Completion of AD 923 Pharmacokinetic,Study in the USA 3Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 2Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 3Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 4
(Date:5/23/2013)... (PRWEB) May 23, 2013 On May 23, ... research and advocacy, commends Salem High School senior Max Merget ... cancer. , According to a Patch.com article, Max ... with anaplastic ependymoma -- a large malignant tumor in the ... He underwent surgery but the tumor came back a year ...
(Date:5/23/2013)... To help members more easily ... pleased to announce integration of its advanced ... new upgrade automatically transfers real-time step data onto ... their company’s team standings, view progress on rewards, ... , Walkingspree also offers an integrated nutritional module ...
(Date:5/23/2013)... South Carolina (PRWEB) May 23, 2013 ... anniversary being in practice. For 25 years, Jeff ... honest legal advice with a focus on personal ... years having worked for insurance companies, he offers clients ... how insurance companies operate, which enables him better serve ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Canadian ... its Max! Healthy Vending Machines, and that's in sync ... report prepared for the Canada Organic Trade Association (COTA). ... organic food and beverages each year. This makes the ... the world. , As a Canadian leader in ...
(Date:5/23/2013)... Portland, Oregon (PRWEB) May 23, 2013 Better ... touches as it prepares to launch its one of ... Final training of management staff will be completed May 29th, ... Chris and Heather Richardson completed on site training in Portland ... the 29th to complete operational training. , "It really is ...
Breaking Medicine News(10 mins):Health News:Voices Against Brain Cancer Commends Young Man for Raising Money for Brain Cancer Despite Fighting His Own Battle 2Health News:Walkingspree Expands Device Options with Fitbit to Increase Member Engagement in Corporate Wellness Programs 2Health News:Walkingspree Expands Device Options with Fitbit to Increase Member Engagement in Corporate Wellness Programs 3Health News:Ezell Law Firm Celebrates 25 Years in Practice 2Health News:Max! Healthy Vending Machines in Tune with Burgeoning Organic Foods Market 2Health News:Better Life Maids of Portland Oregon Prepares For a Summer of 2013 Launch 2
... Alexandria, VA - The 2011 Annual Meeting & OTO ... and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ... convene September 11-14, 2011 in San Francisco, CA. ... and several hundred instruction course hours for attendees, the ...
... effective in helping patients manage their Type 2 diabetes using ... of Maryland School of Medicine researchers. The study is being ... Care . The study, one of the first to scientifically ... blood sugar control the amount of hemoglobin A1c in ...
... Reporter , FRIDAY, July 29 (HealthDay News) -- The ... it uses to approve and regulate "moderate-risk" medical devices ... a highly anticipated federal report released Friday. Instead, ... process that ensures the devices go through more rigorous ...
... College of Radiology and society of Breast Imaging, two top ... issued a statement on a controversial study published in the ... which claimed that there is no evidence that mammography served ... countries where screening has been implemented. , , The ACR ...
... -- The brains of two of four former Canadian ... associated with concussions, say researchers with the Canadian Sports ... (of the Toronto Argonauts and Hamilton Tiger-Cats) and Jay ... encephalopathy (CTE). Both players suffered repeated concussions during their ...
... July 29 (HealthDay News) -- Excluding children from discussions about ... a new study finds. Parents and medical professionals need ... them in decisions, said the researchers from Dublin, Ireland. ... to 18, at three hospitals and found that the kids ...
Cached Medicine News:Health News:World's largest meeting of ear, nose and throat doctors 2Health News:UM School of Medicine finds that mobile phone technology helps patients manage diabetes 2Health News:Report Urges New Review System for Medical Devices 2Health News:Report Urges New Review System for Medical Devices 3Health News:Concussion Project Finds Disease in Two Autopsied Brains 2Health News:Study Finds Kids Want More Info About Their Hospital Care 2
... Codman Sofwire Cable System, ... fixation including sublaminar interspinous ... facial surgery, sternotomy closure. ... and a complete set ...
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%....
... Inductive demineralized bone matrix ... and cancellous chips will be ... bone matrix particle size is ... chip particle size is 1 ...
Demineralized Freeze-dried Bone Allograft (DFDBA) processed from cortical bone. Demineralized cortical powder is free of all soft tissue....
Medicine Products: